Merck & Co., Inc. (NYSE:MRK) Stock Gets Price Target Boost from Freedom Broker

Posted by Grant Hamersma on Nov 2nd, 2026

Merck & Co., Inc. (NYSE:MRK – Get Free Report) had its price target raised by stock analysts at Freedom Broker from $125.00 to $140.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. Freedom Broker‘s price objective points to a potential downside of 5.78% from the stock’s current price.

A number of other brokerages have also commented on MRK. JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Friday. Leerink Partners lifted their price target on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Sanford C. Bernstein lifted their price target on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a research report on Tuesday, August 4th. Citigroup boosted their price objective on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research note on Monday, October 12th. Finally, Rothschild & Co Redburn upped their price objective on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 6th. Seventeen research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $155.85.

View Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Down 0.6%

MRK stock traded down $0.94 during trading hours on Monday, hitting $148.58. The company’s stock had a trading volume of 9,051,364 shares, compared to its average volume of 10,669,300. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $366.58 billion, a PE ratio of 153.18, a price-to-earnings-growth ratio of 6.48 and a beta of 0.21. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92. The stock has a 50 day moving average price of $146.90 and a two-hundred day moving average price of $126.69.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.09 by $0.40. The business had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. Merck & Co., Inc.’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.58 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 2.81 earnings per share for the current year.

Insider Activity

In other news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at $6,106,303. This trade represents a 24.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by company insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of institutional investors have recently modified their holdings of MRK. Bullseye Investment Management LLC bought a new position in Merck & Co., Inc. in the second quarter valued at approximately $27,000. Curry Webb Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at $29,000. Horizons Wealth Management acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at $30,000. Graney & King LLC boosted its position in shares of Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC bought a new position in shares of Merck & Co., Inc. in the 2nd quarter worth $41,000. 76.07% of the stock is owned by institutional investors.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Merck will present new data from its oral HIV portfolio at HIV Glasgow 2026, including Phase 3 analyses and patient-reported outcomes for the investigational once-weekly ISL/LEN combination. Positive data could strengthen confidence in a differentiated, convenient HIV franchise. Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
Positive Sentiment: The company is advancing oral HIV treatment and prevention regimens with once-weekly and once-monthly dosing, while the FDA has accepted supplemental applications for IDVYNSO with a decision expected in 2027. Regulatory progress provides a potential medium-term catalyst. Merck Pushes Ahead With Oral HIV Regimens And 2027 FDA Review
Positive Sentiment: Merck’s personalized melanoma vaccine strategy is attracting investor interest because it could reduce recurrence and support long-term oncology growth beyond the company’s current portfolio. Merck stock rises as its cancer strategy gets personal
Neutral Sentiment: Cantor Fitzgerald raised its price target from $145 to $155 but retained a Neutral rating, signaling modest upside while reflecting uncertainty around the commercial scale-up of newer launches. Merck Stocks Decline With Higher Target Leaving a New-Launch Scale Test
Neutral Sentiment: ETF investors made approximately $22 million of net purchases on October 29, indicating institutional demand, although the flow is not a fundamental earnings catalyst. ETFs Bought $22.0 Million of Merck
Negative Sentiment: Despite earnings beating expectations, MRK’s elevated valuation and the need to prove that new oncology and HIV products can scale are limiting enthusiasm. Analysts’ neutral positioning and reported margin headwinds are contributing to the cautious tone. MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds

About Merck & Co., Inc.

(Get Free Report)

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.